
Opinion|Videos|January 28, 2025
Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
Author(s)Jeffrey V. Matous, MD
Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community practices can be addressed through innovative care models, while reflecting on key insights from ASH 2024 abstracts that could guide broader adoption of these therapies in community settings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the primary barriers preventing widespread use of bispecific antibody therapies in community practices, and what innovative solutions or models of care could help address these challenges?
- Several ASH 2024 abstracts highlighted community center experiences with bispecific antibody therapies. What insights from these studies stand out to you, and how can they guide broader adoption of these therapies in the community setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer
3
Team-Based Precision Oncology: Advancing Value and Access in Cancer Care
4
Navigating Costs and Logistics of Cellular Therapies, ADCs, and Novel Diagnostics in Cancer Care
5
















































